Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod Marketing Approval for Breast Cancer Drug; Share Up 5%

MT Newswires Live11-27 14:28

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said China's National Medical Products Administration (NMPA) gave a marketing authorization for its breast cancer drug, according to a Wednesday filing with the Hong Kong bourse.

The drug is designed for adults with advanced or metastatic triple-negative breast cancer (TNBC) that cannot be surgically removed. It targets TROP2 using the antibody-drug conjugate sacituzumab tirumotecan (sac-TMT, previously SKB264/MK-2870), intended for patients who have already undergone at least two systemic treatments, including one for advanced or metastatic.

The pharmaceutical company's stocks have increased by 5% in recent trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486147897?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-27 14:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486147897","market":"hk","top_or_hot":-1,"title":"Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod Marketing Approval for Breast Cancer Drug; Share Up 5%","media":"MT Newswires Live","content":"<html><body><p> Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said China's National Medical Products Administration (NMPA) gave a marketing authorization for its breast cancer drug, according to a Wednesday filing with the Hong Kong bourse.</p><p>The drug is designed for adults with advanced or metastatic triple-negative breast cancer (TNBC) that cannot be surgically removed. It targets TROP2 using the antibody-drug conjugate sacituzumab tirumotecan (sac-TMT, previously SKB264/MK-2870), intended for patients who have already undergone at least two systemic treatments, including one for advanced or metastatic.</p><p>The pharmaceutical company's stocks have increased by 5% in recent trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod Marketing Approval for Breast Cancer Drug; Share Up 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod Marketing Approval for Breast Cancer Drug; Share Up 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-27 14:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said China's National Medical Products Administration (NMPA) gave a marketing authorization for its breast cancer drug, according to a Wednesday ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0196878994.USD","symbol_name":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2486147897","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486147897","pubTimestamp":1732688887,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sichuan Kelun-Biotech Biopharmaceutical  said China's National Medical Products Administration  gave a marketing authorization for its breast cancer drug, according to a Wednesday filing with the Hong Kong bourse.The drug is designed for adults with advanced or metastatic triple-negative breast cancer  that cannot be surgically removed. It targets TROP2 using the antibody-drug conjugate sacituzumab tirumotecan , intended for patients who have already undergone at least two systemic treatments, including one for advanced or metastatic.The pharmaceutical company's stocks have increased by 5% in recent trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","BK1161":"生物科技","06990":"科伦博泰生物-B"},"translate_title":"四川科伦生物制药获NMPA乳腺癌药物Nod上市批件；股价上涨5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":0.9},"content_text":"Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said China's National Medical Products Administration (NMPA) gave a marketing authorization for its breast cancer drug, according to a Wednesday filing with the Hong Kong bourse.The drug is designed for adults with advanced or metastatic triple-negative breast cancer (TNBC) that cannot be surgically removed. It targets TROP2 using the antibody-drug conjugate sacituzumab tirumotecan (sac-TMT, previously SKB264/MK-2870), intended for patients who have already undergone at least two systemic treatments, including one for advanced or metastatic.The pharmaceutical company's stocks have increased by 5% in recent trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486147897"}